Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM; 'A to Z' Investigators. Blazing MA, et al. Among authors: califf rm. JAMA. 2004 Jul 7;292(1):55-64. doi: 10.1001/jama.292.1.55. JAMA. 2004. PMID: 15238591 Clinical Trial.
Early statin initiation and outcomes in patients with acute coronary syndromes.
Newby LK, Kristinsson A, Bhapkar MV, Aylward PE, Dimas AP, Klein WW, McGuire DK, Moliterno DJ, Verheugt FW, Weaver WD, Califf RM; SYMPHONY and 2nd SYMPHONY Investigators. Sibrafiban vs Aspirin to Yield Maximun Protection From Ischemic Heart Events Post-acute Coronary Syndromes. Newby LK, et al. Among authors: califf rm. JAMA. 2002 Jun 19;287(23):3087-95. doi: 10.1001/jama.287.23.3087. JAMA. 2002. PMID: 12069671
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Petersen JL, et al. Among authors: califf rm. JAMA. 2004 Jul 7;292(1):89-96. doi: 10.1001/jama.292.1.89. JAMA. 2004. PMID: 15238596 Review.
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E; Investigators. de Lemos JA, et al. Among authors: califf rm. JAMA. 2004 Sep 15;292(11):1307-16. doi: 10.1001/jama.292.11.1307. Epub 2004 Aug 30. JAMA. 2004. PMID: 15337732 Clinical Trial.
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, Palmisano J, Ramsey KE, Bilheimer DW, Lewis EF, Pfeffer M, Califf RM, Braunwald E; Investigators. de Lemos JA, et al. Among authors: califf rm. Eur Heart J. 2004 Oct;25(19):1688-94. doi: 10.1016/j.ehj.2004.06.028. Eur Heart J. 2004. PMID: 15451146 Clinical Trial.
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ 3rd, Califf RM; SYNERGY Trial Investigators. Mahaffey KW, et al. Among authors: califf rm. JAMA. 2005 Nov 23;294(20):2594-600. doi: 10.1001/jama.294.20.2594. JAMA. 2005. PMID: 16304073 Clinical Trial.
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Théroux P, Stone GW, Moliterno DJ, Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA. Tricoci P, et al. Among authors: califf rm. Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):448-58. doi: 10.1161/CIRCOUTCOMES.110.960294. Epub 2011 Jun 28. Circ Cardiovasc Qual Outcomes. 2011. PMID: 21712522 Review.
Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.
Lopes RD, White JA, Tricoci P, White HD, Armstrong PW, Braunwald E, Giugliano RP, Harrington RA, Lewis BS, Brogan GX Jr, Gibson CM, Califf RM, Newby LK. Lopes RD, et al. Among authors: califf rm. Int J Cardiol. 2013 Sep 10;167(6):2580-7. doi: 10.1016/j.ijcard.2012.06.053. Epub 2012 Jul 13. Int J Cardiol. 2013. PMID: 22795720 Clinical Trial.
The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.
Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. Blazing MA, et al. Among authors: califf rm. Am Heart J. 2001 Aug;142(2):211-7. doi: 10.1067/mhj.2001.116959. Am Heart J. 2001. PMID: 11479456 Clinical Trial.
1,330 results